Palantir shares slipped after posting Q3 results, as investors expected more than 40% revenue growth for this year and beyond. The post Palantir Might Be Worth the Buy for Patient Investors appeared first on InvestorPlace.
Palantir Might Be Worth the Buy for Patient Investors